ArticleMedicine2026
Integrative bioinformatics analysis of Lianmei granules in diabetic nephropathy: Epidemiological and molecular insights.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Diabetic nephropathy (DN) is a severe complication of diabetes mellitus, leading to end-stage renal disease and significant morbidity. Current therapies are limited by efficacy and side effects, highlighting the need for novel treatments. Lianmei granules (LMG) show potential for treating DN, although their mechanisms remain unclear. This study explored DN epidemiology and investigated the active components, targets, and mechanisms of LMG using a comprehensive bioinformatics approach. We conducted a cross-sectional analysis involving 44,090 participants from the National Health and Nutrition Examination Survey (NHANES) from 2001 to 2023. Given the cross-sectional nature of NHANES, our analytical definition of DN was the presence of diagnosed diabetes and UACR≥30 mg/g in both matched adjacent NHANES cycles. This approach reduced potential false positives from single measurements and approximated clinical diagnostic standards without representing longitudinal follow-up. Multivariate logistic regression identified DN risk factors. LMG active compounds were screened using databases such as TCMSP. Overlapping targets with DN-related genes were identified to construct interaction networks, followed by protein-protein interaction networks, gene ontology/Kyoto Encyclopedia of Genes and Genomes enrichment, gene expression, and immune infiltration analyses. Molecular docking and dynamics simulations were performed. Gender (OR: 1.072, 95% CI: 1.015-1.132, P <.01), race (Non-hispanic black: OR=1.536, 95% CI: 1.412-1.671, P < .001; Mexican Americans: OR = 1.284, 95% CI: 1.165-1.415, P < .001) and hypertension (OR = 1.321, 95% CI: 1.235-1.413, P < .001) were identified as independent risk factors for DN. A total of 215 active LMG compounds and 64 potential DN-related targets were identified, with core targets including prostaglandin-endoperoxide synthase 2, EGFR, ESR1, CYP3A4, and matrix metallopeptidase 9. Enrichment analysis indicated that these targets are mainly involved in cellular responses and hormone signaling. Differential expression analysis (GSE96804) revealed 615 differentially expressed genes, and immune infiltration analysis showed significant immune cell distribution differences between DN and control groups. Molecular docking and dynamics simulations predicted strong binding affinities between key compounds (resveratrol, kaempferol) and core targets (matrix metallopeptidase 9, EGFR). However, further in vitro or molecular studies are needed to validate these mechanisms. This integrative approach underscores the complexity of DN pathogenesis and highlights LMG's potential as a multi-target therapeutic strategy, warranting further investigation into its clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.